Applied Research
Comparative Effectiveness
There is broad support worldwide for medical innovation. At the same time, there is a practical need for societies to make choices and to make sure that limited health care resources are used efficiently.
Comparative effectiveness research examines both the outcomes and the costs of medical technologies. The motivation for comparative effectiveness research is to capture what works in health care, what doesn’t work, what works best, for whom, and under what circumstances.
PI Links
Nancy Neil
Scientific and Medical Communications
We work to review, summarize and communicate clinical concepts, findings, and study results to a variety of audiences, including policy makers, health care practitioners, and patients.
Our work products include:
- Dossier development
- Literature reviews (systematic; non-systematic)
- Natural history/burden of illness reviews
- Peer-reviewed manuscripts and abstracts
- Presentation support
Teaching and Training
We provide teaching and training for those who wish to learn more about comparative effectiveness research in general and/or the hands-on doing of particular types of comparative effectiveness studies (e.g., building clinical decision models; preparing a manuscript for peer review)
Clinical Decision Modeling
The power of a good decision model is its ability to explicitly map out, and quantify the relationships inherent in a complex clinical process. The goal is to help people understand better what is happening, what might happen if certain conditions were changed, and to help focus thinking about a problem, a decision, or alternative choices that might have been difficult to identify otherwise.
We have successfully developed micro-costing, cost-effectiveness, clinical simulation, budget impact, and custom decision models for US and international use in several clinical domains, including serious infection, cardiovascular disease, primary care, gastroenterology, hematology, pulmonology, neurology, urology, and oncology.
Micro-costing Models
- Infusion-related resource use and costs in community hospitals.
- A cost of treatment model for neonates with respiratory distress.
Early-phase Cost-effectiveness Models
- Diagnosis and Treatment of Alzheimer’s Disease.
- Open surgical repair vs. endovascular repair for abdominal aortic aneurysm.
- An economic evaluation of platelet transfusion in chemotherapy-induced thrombocytopenia.
Late-phase Cost-effectiveness Models
- Drug-eluting stents for single-vessel cardiac revascularization.
- A clinical and economic evaluation of drug treatments for overactive bladder.
- Outpatient treatment for overactive bladder.
- Revascularization for femoropopliteal disease.
- CABG vs. coated- or uncoated coronary stents used as single-vessel interventions for patients with coronary artery disease.
- A pharmacoeconomic model comparing two long-acting treatments of overactive bladder.
- CABG vs. coated- or uncoated coronary stents used to treat multi-vessel coronary artery disease.
- Cost-effectiveness of catheter-based radiation therapy for percutaneous coronary revascularization.
Custom Models
- Primary atrial fibrillation: Resource-use associated with choice of initial acute conversion therapy.
- Budget impact of eculizumab for treatment of paroxysmal nocturnal hemoglobinuria (PNH).
- Evidence-based disease management for mild- to moderate-persistent asthma.
- Budget impact of competing management strategies for gastro-esophageal reflux disorder.
- A simulation model of the cost of treatment failure in patients hospitalized with community-acquired pneumonia.
- Primary care treatment of major depressive disorder.
- Clinical and economic model of treatment for CMV-retinitis.
- Clinical and economic outcomes of monotherapy in treating mild to moderate hypertension (US, Canada, France, UK)